Immune System Key Ltd.
Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
It is engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. ISK’s assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment and currently is in phase IIa development stage. The company holds 3 worldwide patents on the molecule and applications.
LATEST NEWS
Grant application to support clinical trial for treatment of Alzheimer’s disease
ISK Ltd and Harvard medical school submitted together grant application to support phase 1B clinical trial for treatment of Alzheimer’s disease.
PHASE 1B/2A Clinical trial started
The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.
Cooperation with Harvard Medical School (MGH)
ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
![Lippman-picture-11-02[1]](https://www.immunesk.com/wp-content/uploads/2019/04/Lippman-picture-11-021-460x295.jpg)
Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK Ltd
Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John G. Searle Professor and Chair of Internal Medicine at the University of Michigan. From 1988 through 1999 he was Professor of Medicine and Pharmacology and Chair, Department of Oncology, at Georgetown University in Washington, DC, and served as Director of the Lombardi Cancer Center. Dr. Lippman served as Head of the Medical Breast Cancer Section, Medicine Branch, at the NIH. He completed a Fellowship in
